Year-end retrospectives aside, taking the figurative pulse of an industry as large and varied as biotechnology is anything but easy. But during what everybody acknowledges were tight economic times, a notable trend was the continued interest by venture capital, especially in the field of anti-infectives. (BioWorld Financial Watch)